Literature DB >> 9589828

Overview of atherosclerosis.

W B Kannel1.   

Abstract

Cardiovascular disease is a serious threat to both life and health, accounting for 44% of the nation's mortality and much of its morbidity. Moreover, atherosclerotic cardiovascular disease is a growing problem because of the aging population. Coronary heart disease is the most common cause of lethal atherosclerotic disease, accounting for two thirds of all deaths resulting from heart disease and 70% of all deaths in those older than 75. A 1997 estimate put the economic cost of atherosclerotic cardiovascular disease at a staggering $259 billion. Indications are that atherosclerotic cardiovascular disease is a generalized process that involves the heart, brain, and peripheral arteries. Clinical manifestations tend to coexist, and the presence of one manifestation increases the likelihood of developing others, because major risk factors tend to affect all arterial territories. Also, clinical atherosclerosis in one area may directly predispose the patient to occurrence of atherosclerosis in another vascular territory. Therefore, measures taken to prevent one clinical manifestation of atherosclerosis should prevent the others as well. Multivariate risk profiles can identify persons at risk for atherosclerotic cardiovascular disease and target them for preventive treatment. Primary preventive measures also appear to be applicable to secondary prevention. Meta-analyses of randomized trials of the efficacy of low-dose aspirin and other antiplatelet agents in persons with overt cardiovascular disease have shown reductions of approximately 25% in the incidences of subsequent myocardial infarctions, strokes, and cardiovascular mortality. Comparison of the risk profiles for atherosclerotic cardiovascular disease indicates that correction of any particular set of risk factors or prevention of any cardiovascular disease outcome prevents other atherosclerotic disease outcomes as well. The challenge for all health care professionals is to implement comprehensive preventive measures for those at high risk for initial atherosclerotic events and even more vigorous measures for those who already have the disease.

Entities:  

Mesh:

Year:  1998        PMID: 9589828     DOI: 10.1016/s0149-2918(98)80027-1

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  11 in total

1.  3D Cryo-Section/Imaging of Blood Vessel Lesions for Validation of MRI Data.

Authors:  Olivier Salvado; Debashish Roy; Meredith Heinzel; Eliot McKinley; David Wilson
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2006-03-01

2.  Protection of salvianolate against atherosclerosis via regulating the inflammation in rats.

Authors:  Chun Meng; Xiao-Qing Zhuo; Guo-Hong Xu; Jian-Li Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-10-16

Review 3.  Statin therapy in the elderly: does it make good clinical and economic sense?

Authors:  Moira M B Mungall; Allan Gaw; James Shepherd
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

4.  FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries.

Authors:  Gonca G Bural; Drew A Torigian; Wichana Chamroonrat; Mohamed Houseni; Wengen Chen; Sandip Basu; Rakesh Kumar; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-24       Impact factor: 9.236

5.  Interactions between Panax quinquefolium saponins and vitamin C are observed in vitro.

Authors:  J P Li; M Huang; H Teoh; R Y Man
Journal:  Mol Cell Biochem       Date:  2000-01       Impact factor: 3.396

6.  Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart.

Authors:  Joerg Heineke; Mannix Auger-Messier; Jian Xu; Toru Oka; Michelle A Sargent; Allen York; Raisa Klevitsky; Sachin Vaikunth; Stephen A Duncan; Bruce J Aronow; Jeffrey Robbins; Timothy M Crombleholme; Timothy M Cromblehol; Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

7.  Internet based vascular risk factor management for patients with clinically manifest vascular disease: randomised controlled trial.

Authors:  J W P Vernooij; H A H Kaasjager; Y van der Graaf; J Wierdsma; H M H Grandjean; M M C Hovens; G A de Wit; F L J Visseren
Journal:  BMJ       Date:  2012-06-12

8.  The dynamics of mortality in follow-up time after an acute myocardial infarction, lower extremity arterial disease and ischemic stroke.

Authors:  Ilonca Vaartjes; Ineke van Dis; Diederick E Grobbee; Michiel L Bots
Journal:  BMC Cardiovasc Disord       Date:  2010-11-25       Impact factor: 2.298

9.  Cost-effectiveness of a nurse-led internet-based vascular risk factor management programme: economic evaluation alongside a randomised controlled clinical trial.

Authors:  J P Greving; H A H Kaasjager; J W P Vernooij; M M C Hovens; J Wierdsma; H M H Grandjean; Y van der Graaf; G A de Wit; F L J Visseren
Journal:  BMJ Open       Date:  2015-05-20       Impact factor: 2.692

10.  Correlation of Serum Levels of Vitronectin, Malondialdehyde and Hs- CRP With Disease Severity in Coronary Artery Disease.

Authors:  Alireza Yaghoubi; Morteza Ghojazadeh; Sakhavat Abolhasani; Hossein Alikhah; Fatemeh Khaki-Khatibi
Journal:  J Cardiovasc Thorac Res       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.